Any current/future new fundraising through debt or equity?

There is no specific mention of any current or upcoming fundraising through debt or equity in the provided transcript. The company did mention that they approached capital markets earlier to raise IPO funds to support growth, particularly for CapEx in Mambattu and Khalapur plants. All expansions and enhanced CapEx requirements (such as 2.5x increase in Mambattu) are being funded through internal accruals. No new external fundraising plans, either debt or equity, were explicitly stated for the ongoing or future projects during this earnings call.

Any current/future capex/capital investment/strategic investment?

**Mambattu Plant (Andhra Pradesh):** - Original CapEx planned at INR 20 crores for a 5-tank, simple blending facility. - Enhanced 2.5 times to include 10-12 tanks with helium and semiconductor gas capabilities, and hydrocarbon handling. - Revised CapEx significantly higher than INR 20 crores; timeline extended to January/February 2026. - Entire enhancement funded through internal accruals. **Khalapur Facility:** - CapEx around INR 30 crores (original IPO plan INR 50-52 crores for combined Mambattu and Khalapur). - Expanded design for 300 bar pressure handling. - Expected to be r

Future growth expectations in sales/revenue/volumes?

Stallion India Fluorochemicals targets a 30%-35% CAGR growth over the next three years. Total revenue guidance for FY2526 is INR 430 crores, with over 50% already achieved in H1. Growth drivers include higher volumes, improved product mix, and strong demand across key end-user industries. Expansion of HFO blending and debulking capacity, semiconductor gases, and helium-processing capabilities. New facilities at Bhilwara (Rajasthan) and Mambattu (Andhra Pradesh) will enhance backward integration and product offerings. Rajasthan plant revenue potential estimated at INR 500-700 crores by 2028 wit

Future growth expectations in earnings/operating earnings/profits/EPS?

Stallion India targets a revenue of INR 430 crores and PAT of INR 40 crores for FY2526, with confidence in achieving these goals supported by strong H2 performance. The company expects a 30%-35% CAGR growth over the next three years driven by backward and forward integration initiatives, enhancing operating margins by 3%-4%. Expansion projects at Bhilwara (R32 manufacturing), Mambattu, Khalapur, and Rajasthan plants are expected to significantly boost revenues and profits. Rajasthan plant alone targets INR 500-700 crores revenue by 2028 with a 24% PAT margin. Entry into semiconductor gases and

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the current or expected order book or pending orders for Stallion India Fluorochemicals Limited. However, there is strong confidence expressed in achieving revenue targets, with over 50% of the full-year revenue guidance of INR 430 crores already achieved in the first half of FY2526. The company is progressing well on multiple facilities and expansions, such as the Bhilwara R32 manufacturing facility and the upcoming Mambattu and Rajasthan plants, which signal strong future order flow potential. Management highlighted close and well-defined mile

Stallion India Fluorochemicals LtdQ2 FY26Chemicals & Petrochemicals

Stallion India Fluorochemicals Ltd Q2 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹186.76P/E: 41.7Market Cap: ₹2.2K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

Yes

Order

N/A

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

Stallion India Fluorochemicals targets a 30%-35% CAGR growth over the next three years.
Total revenue guidance for FY2526 is INR 430 crores, with over 50% already achieved in H1.
Growth drivers include higher volumes, improved product mix, and strong demand across key end-user industries.
Expansion of HFO blending and debulking capacity, semiconductor gases, and helium-processing capabilities.
New facilities at Bhilwara (Rajasthan) and Mambattu (Andhra Pradesh) will enhance backward integration and product offerings.
Rajasthan plant revenue potential estimated at INR 500-700 crores by 2028 with a PAT margin of 24%.
Incremental revenues from HFO and helium segments expected to increase annually by INR 50-200 crores.
Q3 and Q4 expected to outperform Q1 and Q2, traditionally weaker quarters.
Backward integration in critical raw materials like R32 planned by 2028 to ensure sustained growth.

Margin guidance

Category 1

Stallion India targets a revenue of INR 430 crores and PAT of INR 40 crores for FY2526, with confidence in achieving these goals supported by strong H2 performance.
The company expects a 30%-35% CAGR growth over the next three years driven by backward and forward integration initiatives, enhancing operating margins by 3%-4%.
Expansion projects at Bhilwara (R32 manufacturing), Mambattu, Khalapur, and Rajasthan plants are expected to significantly boost revenues and profits.
Rajasthan plant alone targets INR 500-700 crores revenue by 2028 with a 24% PAT margin.
Entry into semiconductor gases and helium segments, supported by backward integration (e.g., AHF and MDC production), is projected to add incremental revenues of INR 500 crores at ~20% PAT.
The company expects EBITDA margins to improve beyond current levels due to these expansions and integration efforts.
Overall, the growth strategy focuses on operational excellence, product diversification, and leveraging patent-protected products for sustainable profitability expansion.

See what Stallion India Fluorochemicals Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

There is no specific mention of any current or upcoming fundraising through debt or equity in the provided transcript.
The company did mention that they approached capital markets earlier to raise IPO funds to support growth, particularly for CapEx in Mambattu and Khalapur plants.
All expansions and enhanced CapEx requirements (such as 2.5x increase in Mambattu) are being funded through internal accruals.
No new external fundraising plans, either debt or equity, were explicitly stated for the ongoing or future projects during this earnings call.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders for Stallion India Fluorochemicals Limited.
However, there is strong confidence expressed in achieving revenue targets, with over 50% of the full-year revenue guidance of INR 430 crores already achieved in the first half of FY2526.
The company is progressing well on multiple facilities and expansions, such as the Bhilwara R32 manufacturing facility and the upcoming Mambattu and Rajasthan plants, which signal strong future order flow potential.
Management highlighted close and well-defined milestones for project completion, suggesting an active and continuous pipeline of orders and capacity expansion.
The increased focus on semiconductor gases and integration initiatives points toward expected growth in order inflow in high-margin segments.
Overall, while no explicit order book numbers were disclosed, ongoing expansions and confident revenue targets imply a healthy and growing order pipeline.

See what Stallion India Fluorochemicals Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Mambattu Plant (Andhra Pradesh):
- Original CapEx planned at INR 20 crores for a 5-tank, simple blending facility.
- Enhanced 2.5 times to include 10-12 tanks with helium and semiconductor gas capabilities, and hydrocarbon handling.
- Revised CapEx significantly higher than INR 20 crores; timeline extended to January/February 2026.
- Entire enhancement funded through internal accruals.
Khalapur Facility:
- CapEx around INR 30 crores (original IPO plan INR 50-52 crores for combined Mambattu and Khalapur).
- Expanded design for 300 bar pressure handling.
- Expected to be ready by December 2025 or January 2026.
- Foundations and infrastructure scaled for future capacity.
Bhilwara Facility (Rajasthan):
- R32 manufacturing plant with INR 200 crores CapEx.
- Commissioning expected by July 2026.
- Revenue potential INR 500-700 crores by 2028 with around 24% PAT margin.
- Not covered under IPO CapEx; focusing on backward integration.
Strategic Focus:
- Expanding semiconductor gases and helium processing capacity.
- Aim for backward integration in raw materials to enhance margins and control.

Track Stallion India Fluorochemicals Ltd — get its next earnings analysis in your feed

How does Stallion India Fluorochemicals Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisStallion India Fluorochemicals Ltd

Rev 2Mar 1

See where Stallion India Fluorochemicals Ltd sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Stallion India Fluorochemicals Ltd rank in Chemicals & Petrochemicals?

Compare Stallion India Fluorochemicals Ltd against every Chemicals & Petrochemicals company (Q2 FY26) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

What Stallion India Fluorochemicals Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

POCL Enterprises Ltd (Q1 FY27)
466.03 crores (Page 12, 17, 11) . Key investor presentation takeaways from POCL Enterprises Ltd's Q1 FY27 investor presentation — and how it ranks against secto
Deepak Nitrite Ltd (Q2 FY27)
Q2 FY27 total revenue: ₹3,091 crore, up 61% YoY (Page 1, 4, 5, 6, 10, 11) . Key investor presentation takeaways from Deepak Nitrite Ltd's Q2 FY27 investor prese
Privi Speciality Chemicals Ltd (Q2 FY27)
19,239.47 lakhs (approximately 33.9% growth). Key results statement takeaways from Privi Speciality Chemicals Ltd's Q2 FY27 results statement — and how it ranks
NOCIL Ltd (Q2 FY27)
427 crores . Key investor presentation takeaways from NOCIL Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.

Compare:vs Solar Industries vs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →